A Review of Gene Therapy in Canine and Feline Models of Lysosomal Storage Disorders
- 1 March 2015
- journal article
- review article
- Published by SAGE Publications in Human Gene Therapy Clinical Development
- Vol. 26 (1) , 27-37
Abstract
Lysosomal storage disorders (LSDs) are inherited diseases that result from the intracellular accumulation of incompletely degraded macromolecules. The majority of LSDs affect both the peripheral and central nervous systems and are not effectively treated by enzyme replacement therapy, substrate reduction therapy, or bone marrow transplantation. Advances in adeno-associated virus and retroviral vector development over the past decade have resurged gene therapy as a promising therapeutic intervention for these monogenic diseases. Animal models of LSDs provide a necessary intermediate to optimize gene therapy protocols and assess the safety and efficacy of treatment prior to initiating human clinical trials. Numerous LSDs are naturally occurring in large animal models and closely reiterate the lesions, biochemical defect, and clinical phenotype observed in human patients, and whose lifetime is sufficiently long to assess the effect on symptoms that develop later in life. Herein, we review that gene therapy in large animal models (dogs and cats) of LSDs improved many manifestations of disease, and may be used in patients in the near future.Keywords
This publication has 131 references indexed in Scilit:
- Systemic Administration of AAV8-α-galactosidase A Induces Humoral Tolerance in Nonhuman Primates Despite Low Hepatic ExpressionMolecular Therapy, 2011
- Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman PrimatesMolecular Therapy, 2011
- Long-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene TransferMolecular Therapy, 2011
- Safe, Efficient, and Reproducible Gene Therapy of the Brain in the Dog Models of Sanfilippo and Hurler SyndromesMolecular Therapy, 2011
- Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene TherapyMolecular Therapy, 2010
- Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type IMolecular Genetics and Metabolism, 2010
- Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expressionMolecular Genetics and Metabolism, 2010
- Magnetic resonance spectroscopy of the occipital cortex and the cerebellar vermis distinguishes individual cats affected with alpha‐mannosidosis from normal catsNMR in Biomedicine, 2009
- Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapyMolecular Genetics and Metabolism, 2008
- Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosisMolecular Genetics and Metabolism, 2008